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Background: Severe Alpha-1 Antitrypsin (AAT) deficiency is a hereditary condition caused by mutations in the
SERPINA1 gene, which predisposes to lung emphysema and liver disease. It is usually related to PI*Z alleles, and less
frequent to rare and null (QO) alleles. Null-AAT alleles represent the end of a continuum of variants associated with
profound AAT deficiency and extremely increased risk of emphysema.
Methods: A family with severe AAT deficiency was analyzed to achieve genetic diagnosis. The complete exons and
introns of the SERPINA1 gene were sequenced and transcriptional analysis by RT-PCR was performed to characterize
the effect of splicing variants found in the patients. In addition, a minigene MGserpa1_ex1b-1c was cloned into the
pSAD vector to in vitro investigate the independent impact of variants on splicing process.
Results: We report a new identified null allele (PI*QOMadrid) in two adult siblings with practically no detectable
serum AAT. The PI*QOMadrid allele consist of a duplication of the thymine (T) in position +2 of the donor splice site
of exon 1C (+2dupT). In these two subjects, PI*QOMadrid occurred in compound heterozygote combination with the
previously described variant PI*QOPorto. Both QOMadrid and QOPorto variants are located very close together in a
regulatory region of the SERPINA1 gene. Analysis of transcripts revealed that QOMadrid variant prevented the
expression of transcripts from exon 1C, and then normally spliced RNA products are not expected in the liver of
these patients. In addition, aberrant splicing patterns of both variants were clearly distinguished and quantified by
functional in vitro assays lending further support to their pathogenicity.
Conclusion: Finding pathogenic mutations in non-coding regions of the SERPINA1 highlight the importance that
regulatory regions might have in the disease. Regulatory regions should be seriously considered in discordant cases
with severe AAT deficiency where no coding mutations were found.
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Human alpha-1 antitrypsin (AAT), also named alpha-1
protease inhibitor (α1-PI) and SERPINA1 (Serine Protease
Inhibitor, group A, member 1), is a circulating glycoprotein
with a broad spectrum antiserine-protease activity, includ-
ing the inhibition of free elastase from neutrophil. AAT* Correspondence: bmartinezd@isciii.es
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unless otherwise stated.acts mainly as an acute phase reactant but also has anti-
inflammatory, anti-infectious and immunomodulation
effects [1,2]. Deficiency of AAT leads to lung tissue
damage and emphysema due to uncontrolled elastase
activity, or liver disease caused by accumulation within
the hepatocytes of misfolded, aggregated AAT protein [3].
Severe AAT deficiency is an inherited condition char-
acterized by AAT serum levels below 35% (or 50 mg/dL)
the normal value. The protein is codified at the protease
inhibitor locus (14q32.1), by the SERPINA1 gene, which
is organized into three non-coding exons (1A, 1B and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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gene is inherited following an autosomal co-dominant
pattern [5].
Over 80% of AAT is synthesized in the liver, although
other cell types such as blood monocytes, neutrophils,
macrophages, pancreas, endothelium, enterocytes, lung
alveolar and some cancer cells are also capable of secret-
ing additional quantities [6,7]. Transcriptional regulation
occurs in at least two different sites within the gene: the
hepatocyte promoter located upstream the transcription
start site of exon 1C, and the monocyte promoter located
upstream of exon 1A [8].
More than one hundred different genetic variants have
been already described in detail and a wide knowledge
about how these alterations affect the protein conform-
ation and function has been learnt in the last decades
[9]. Allelic variants of AAT are conventionally classified
as normal and deficient [1,3,5,10]. The most common
normal AAT alleles are PI*M1 (rs6647; NM_000295.4:
c.710 T > C; p.Val213Ala, mature protein), PI*M2
(rs709932; c.374G > A; p.Arg101His) and PI*M3 (rs1303;
c.1200A > C; p.Glu376Asp). The allelic frequency of these
polymorphisms varies among populations being M1
(24%), M2 (13%), and M3 (23%) (minor allele frequency
source:1000 Genomes). In contrast to normal AAT alleles,
there are two categories of genetic variants that cause
AAT deficiency: the deficient and the null alleles.
The most common deficient alleles are PI*S (rs17580:
c. 863A > T; p. Glu264Val) and PI*Z (rs28929474;
c.1096G > A; p.Glu342Lys), with a PI*S prevalence in
Caucasians of 5-10% [11] (3%, 1000 Genomes) and a
PI*Z prevalence of 1-3% (0.7%, 1000 Genomes). Normal
serum levels are associated with M alleles. In contrast
reduced levels are associated with the PI*S and PI*Z
alleles with AAT serum levels of 40% and 10-20%,
respectively. Then, the PI*Z allele is related to severe
deficiency and is the phenotype most often associated
with the disease.
There are also other rare variants, with a lower fre-
quency ranging from 1 × 10−4 to 2.5 × 10−5, and around
15% serum AAT [10,12]. Both PI*S and PI*Z, and rare
deficiency alleles MMalton, MDuarte, and SIiyama produce
misfolded proteins which are retained into hepatocytes
forming polymers, which can cause cell stress and
liver damage, and on the other hand, as a result of
polymerization/retention into hepatocytes, reduced blood
and tissues concentration of AAT, insufficient to protect
tissues against proteases [9,13].
In the last two decades about 25 null variants, associated
with trace amounts (<1%) of plasma AAT, have been
discovered (Table 1) [4,10,12,14-26]. Although little
information about their prevalence is available, it is thought
that they are extremely infrequent, with an estimated
combined frequency of 1.4 × 10−4 among Caucasians. Infact, the few published cases of carriers of null alleles have
been found on European and European-American individ-
uals, with only three carriers found in descendants of
Egyptians, African-Americans and Chinese. Notably, des-
pite their low prevalence, null variants have a strong effect
on phenotype, conferring an extraordinary risk to develop
severe pulmonary emphysema [19,27,28]. The majority
of these variants cause premature stop codons in the
SERPINA1 gene leading to either unstable mRNA or trun-
cated, unstable proteins (i.e. QOGranite Falls, QOMattawa,
QOHong Kong, QOBellingham). Other mechanisms include
complete gene deletion (QOIsola di Procida), missense
mutations which probably destabilize the AAT protein
(QOLudwigshafen and QONew Hope), or mutations affecting
the RNA splicing process (QOWest, QOBonny Blue, QOPorto)
[4,29]. Although infrequent, AAT null variants have
allowed a better understanding of the molecular basis of
the disease and revealed functionally critical regions of the
gene sequence [27].
Although other previously described AAT null alleles
have been reported in Spain [10], now we describe the
first new AAT null allele in Spain, in a Caucasian fam-
ily from Madrid, designated as QOMadrid, as this city
was the place of birth and residence of the index-case,
as well as his three siblings and parents. These family
cases showed a combination of two rare splicing vari-
ants in the donor splice site of intron 1C, QOPorto and
the new allele QOMadrid. Molecular characterization of
these mutations located in regulatory region of the
gene, allowed as to better understand the mechanisms
of transcription and alternative splicing of SERPINA1
gene.
Methods
Patients
The family was composed by four siblings, three males
and one female, two of them PI*QOPorto/QOMadrid
compound heterozygotes with severe AAT deficiency,
and the remaining ones PI*M/QOPorto as well hetero-
zygotes but with moderate AAT deficiency (Figure 1).
Their parents died years ago, and none of them had de-
scendants or other blood relatives. Signed informed
consent for the study was obtained from patients.
All these patients were previously characterized for AAT
serum levels, AAT protein phenotype and genotyping of
the common PI*S and PI*Z alleles. The determination of
serum AAT was conducted by immunonephelometry with
an autoanalyzer ArrayTM Protein System (Beckman-In-
struments, Brea, California, USA).
Protease inhibitor (PI) typing was made by means of
isoelectric focusing (IEF) technique as previously de-
scribed [10,35]. All four siblings were studied for the
existence of AAT protein variants by IEF but conclusive
patterns were not found.
Table 1 Molecular and clinical features of known 21 PI*QO (Null) alleles
Allele Molecular basis of disease Clinical features Reference
QOamersfoort Exon 2. Tyr160 stop. Nonsense mutation
producing a stop at codon 160, and a
premature termination in exon 2 with
no detectable mRNA
The index patient was a Caucasian
47-year-old female patient who
had COPD
[30]
QObellingham Exon 3. Lys217 stop codon. High risk of emphysema in
homozygotes and compound
heterozygotes
[31]
No detectable AAT mRNA
QObolton Exon 5. Δ1bpPro362 causing stop codon
at 373. Truncated protein, degraded, not
secreted
High risk of emphysema in
homozygotes and compound
heterozygotes
[17]
QObonny blue ΔG deletion position #1 of intron II
splice acceptor
High risk of emphysema in
homozygotes and compound
heterozygotes
[4]
QOcairo Exon 3. Lys259 stop codon. Truncated
protein, degraded, not secreted protein.
High risk of emphysema in
homozygotes. One carrier belonged
to an Italian/Egyptian family, and 2
other to a family from Southern Italy
[26]
QOclayton Exon 5. Pro362 insC causing stop codon
at 376. Truncated protein, degraded and
not secreted
High risk of emphysema in
homozygotes and compound
heterozygotes
[14]
QOdevon (=QOnewport) Exon 2. Gly115Ser. Intracellular degradation
and reduced serum concentration
Risk of emphysema and liver disease
in compound heterozygotes with Z
allele. Unclear whether Gly115Ser
would cause disease in absence of
Z mutation
[32]
QOgranite falls Exon 2. Δ1bpTyr160 causing stop codon.
No detectable AAT mRNA
Severe emphysema reported in an
American black family Z compound
heterozygote
[21]
QOhong Kong Exon 4. Δ2bpLeu318 causing stop codon
at 334. Truncated protein; degraded and
not secreted
High risk of emphysema in
homozygotes and compound
heterozygotes. Reported in Chinese
descents.
[24]
QOisola di procida Δ17 Kb inc. exons II –V. No detectable
AAT mRNA
Emphysema reported in compound
heterozygote
[33]
QOlisbon Exon 2. Thr68Ile. High risk of emphysema in
homozygotes.
[16]
50% normal serum AAT in M/QOLisbon
heterozygotes
QOludwisghafen Exon 2. Ile92Asn. Intracellular degradation
and no secreted protein
High risk of emphysema in homozygotes
and compound heterozygotes
[18]
QOmadrid Intron 1C, c.-5 + 2dupT. Duplication of
thymine in position +2 of the donor
splice site, causing no expression of
mRNA transcripts
Index case: a compound heterozygote
QOmadrid /QOporto with COPD. Three
heterozygote siblings with radiological
findings of lung disease.
[current report]
QOmattawa (M1allele) and
QOourém (M3 allele)
Exon 5. Same mutation Leu353Phe
causing stop codon at 376, in M1 and
M3 respectively. Truncated protein,
degraded, not secreted, reduced serum
levels
Lung emphysema reported in
homozygotes
[15,25,29]
QOmilano Exon 3, 17 bp deletion (AAA CTA CAG
CAC CTG GA), causing a stop codon
downstream. Truncated protein lacking
of active site
Heterozygote M/QOmilano Italian child
with persistently increased in liver
enzymes and a mild decrease in serum
AAT levels
[23]
QOnew hope Exon 4, 5. Gly 320 GGG→ Glu GAG/Glu
342 GAG→ Lys AAG
High risk of emphysema in homozygotes
and compound heterozygotes
[4]
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Table 1 Molecular and clinical features of known 21 PI*QO (Null) alleles (Continued)
QOporto Intron 1C, c.-5 + 1G > A. Splicing site
variant, causing no expression of mRNA
transcripts.
High risk of emphysema in homozygotes. [29]
QOriedenburg Whole gene deletion. No AAT gene
expression
High risk of emphysema in
homozygotes and compound
heterozygotes
[22]
QOsaarbueken Exon 5. 1158dupC causing stop codon
at 376. Truncated protein; not secreted
High risk of emphysema in
homozygotes.
[16]
50% normal serum AAT in
M/QO Saarbueken heterozygotes
QOsoest Exon 2. Thr102delA, which produces a
TGA stop signal at codon 112
Index case: a homozygote 46-year-old
man with severe COPD
[30]
QOtrastevere Exon 3. Try194 stop codon. Intracellular
degradation of truncated protein; not
secreted
Emphysema reported in an Italian
compound heterozygote
[20]
QOwest G → T position +1 of intron 2 splice
donor substitution. ΔGly164- Lys191.
Aberrant mRNA splicing, intracellular
degradation and no detectable protein
Emphysema reported in a compound
heterozygote
[34]
Moderate DAAT
Severe DAAT
II-1 II-2 II-3 II-4
I-1 I-2
67 mg/dL 72 mg/dL 8,7 mg/dL 9 mg/dL[AAT]:
QOPorto
M2(A)
M3 (C)
QOPorto
M2 (A)
M3 (C)
QOMadridQOPorto
M2 (A)
M3 (C)
QOMadridQOPorto
M2(A)
M3 (C)
Figure 1 Pedigree of the family studied. Both parents (I-1 and I-2) were dead when the AAT study was performed. The four siblings studied
correspond to 3 males (II-1, II-2 and II-4) and a female (II-3). The index case is II-4, indicated by the arrow. None of them had any children. Allele
combination of the QOPorto and QOMadrid mutations and the normal variants, M2 (G/A, Arg101His) and M3 (A/C, Glu376Asp) found in each
individual are depicted below each family member. Corresponding AAT serum level are also shown.
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the commonest defective variants PI*Z and PI*S by a
LightCycler PCR, using primers and hybridization
probes as described before [36]. None of these com-
mon deficient variants were found in our cases.
Sequence analysis of the entire SERPINA1 gene
Since the low serum AAT concentration of the subjects
could not be attributed to PI*Z genotypes, the entire
coding sequence of the SERPINA1 gene was analyzed
(Reference sequences NG_008290.1, NM_000295.4). Exons
2 to 5 and exon-intron junctions were analyzed by means
of a Sanger automated sequencing, using previously
described primers [37]. After that, to exclude the exist-
ence of other rare variants outside coding regions of
the gene, primers for amplification of additional gene
fragments to cover the whole gene were designed
(Additional file 1: Table S1). The entire gene sequence
were analyzed by Sanger automated sequencing (ABI
PRISM 377 Applied BioSystems) in the four studied in-
dividuals of the family.
Expression analysis by RT-PCR
RNA extraction from peripheral blood was performed
using RNAeasy kit (Quiagen) following manufacturer’s
recommendations. Then, cDNA synthesis was carried
out by reverse transcription PCR (RT-PCR) using the
Maxima First Strand cDNA Synthesis kit (Thermo
Scientific). To analyze transcripts and splicing (from
normal hepatocytes and peripheral blood samples) oc-
curring in patients and controls, the regions between
E1A/E2, E1B/E2 and E1C/E2 or E1C/E5 were amplified
using several primers located in exon 1A, 1B, 1C, exon 2
and exon 5 as follows: E1A-F: 5′-TCCTGTGCCTGCC
AGAAGAG-3′; E1B-F, 5′-ATCAGGCATTTTGGGGTG
ACT-3′ [29]; E1C, 5′CTGTCTCCTCAGCTTCAGGC3′;
E2-R, 5′-TTCTTGGCCTCTTCGGTGTC-3′ and E5-R,
5′-CCATGAAGAGGGGAGACTTGG-3′. In addition, a
primer localized in the initial region of intron 1C INT1C,
5′-GGGGATGGAGAATGTGAGCC-3′ was also used to
analyze the existence of possible transcripts using intron
sequence in mutant cases. PCR amplification of the
different products was performed under the following
conditions: 35 cycles of 94°C for 45 s, 60°C for 45 s,
and 72°C for 45 s. Amplified products were visualized
in 1-2% agarose gels, purified by PCR purification Kit
(Qiagen) and subsequently cloned into pGEM-T easy
vector (Promega, Madison WI, USA) or directly ana-
lyzed by sequencing with an ABI PRISM 377 sequen-
cer. Ligation reactions were used to transform DH5α
competent cells. Clones containing PCR products were
selected by blue/white colony and standard ampicillin
selection. Positive transformants were analyzed by PCR
and sequenced using AAT primers.Computational predictions
By using different prediction methods integrated in
Alamut 1.3 software we evaluated splice signal detec-
tion (SpliceSiteFinder-like, MaxEntScan, GeneSplicer,
Human Splicing Finder or Known constitutive signals)
and Exonic Splicing Enhancers ESE binding site detection
(ESEFinder) comparing reference and mutated sequences.
Construction of the Minigene MGserp1a_ex1b-1c
In order to analyze the effect of the splicing variants, a
minigene containing exons 1B and 1C with the flanking
intronic sequences were constructed. Exons 1B and 1C
and part of the flanking intronic sequences (1,252 bp;
Additional file 2: Figure S2) were amplified with Phusion
High Fidelity polymerase (Fisher Scientific, Madrid, Spain)
and forward, 5′ GCTCTAGAACTAGTGGATCCCCCGGG
GAGCAAAAACAGAAACAGG 3′ and reverse, 5′ ATAA
GCTTGATATCGAATTCCTGCACTTTGTTGCTGTTG
CTGTATC 3′ primers (cloning tails are in italics). This
fragment was cloned into the pSAD® splicing vector
(patent# P201231427, Consejo Superior de Investiga-
ciones Científicas, Spain) by overlap extension PCR
[38], transformed into the DH5α strain of Escherichia
coli (Life Technologies, Carslbad, CA, USA), and plated on
LB-agar with ampicillin (Fisher Scientific) at 100 μg/μL, X-
Gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside,
Fisher Scientific) at 40 μg/μL and IPTG 0.1 mM (isopropyl
beta-D-thiogalactopyranoside, Fisher Scientific), where re-
combinant white colonies were selected. This construct
constituted the minigene MGserp1a_ex1b-1c.
In vitro expression analysis of splicing variants QOPorto
and QOMadrid by site directed mutagenesis of the
Minigene MGserp1a_ex1b-1c
To include in the minigene the studied genetic variants,
mutagenesis was carried out according to PCR muta-
genesis protocol over the wild type minigene by using
Pfu UltraHF polymerase (Agilent, Santa Clara, CA) and
primers for variant c.-5 + 1G > A (QOPorto) (F:5′ACTG
ACCTGGGACAGTGAATCATAAGTATGCCTTTCA
CTGCGA3′, R: 5′TCGCAGTGAAAGGCATACTTA
TGATTCACTGTCCCAGGTCAGT3′) and for variant
QOMadrid, c.-5 + 2dupT (F:5′CTGACCTGGGACAGTG
AATCGTTAAGTATGCCTTTCACTGCGAGA3′, and
R:5′TCTCGCAGTGAAAGGCATACTTAACGATTCA
CTGTCCCAGGTCAG3′).
For transfection, approximately 105 HeLa (human
cervical carcinoma) cells were grown to 90% confluency in
0.5 mL of medium (DMEM, 10% Fetal Bovine Serum, 1%
glucose and 1% Penicillin/Streptomycin; Fisher Scientific)
in 4-well plates (Nunc, Roskilde, Denmark). Cells were
transfected with 1 μg of each minigene and 2 μL of
Lipofectamine 2000 (Life Technologies). To inhibit non-
sense mediated decay (NMD), cells were incubated with
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(4 hours).
To analyze the expression products generated by the
insertion of the variants, firstly
RNA from transfected cells was purified with the Gene-
MATRIX Universal RNA purification kit (EURx, Gdansk,
Poland) with DNAse I treatment. Then, retrotranscription
was carried out with 400 ng of RNA and the Transcriptor
first strand cDNA synthesis kit (Roche Applied Science,
Penzberg, Germany) and sequence specific primer SA2-
PSPL3_RTREV (5′TGAGGAGTGAATTGGTCGAA3′)
that retrotranscribes only RNA produced by the mini-
gene. Two to five μL of cDNA were amplified with
Platinum Taq polymerase (Life Technologies) and spe-
cific RT-PCR primers of the vector exons, SD6-
PSPL3_RTFW (5′-TCACCTGGACAACCTCAAAG-3′)
and SA2-PSPL3_RTREV. Samples were denatured at 94°C
for 5 min, followed by 35 cycles consisting of 94°C for
30 sec, 59°C for 15 sec, and 72°C (1 min/kb), and a final
extension step at 72°C for 5 min.
Semiquantitative fluorescent RT-PCRs were done with
FAM-labelled SD6-PSPL3_RTFW primer as previously
reported [39]. One μL of a dilution 1/10-1/20 of the RT-
PCR products was mixed with 18.5 μL of Hi-Di Form-
amide (Life Technologies) and 0.5 μL of Genescan 500
Rox Size Standard (Life Technologies). To visualize the
expression products, samples were run on an ABI3130
sequencer and analyzed with Peak Scanner (Life
Technologies).
Results
Clinical and phenotypic characteristics of patients
The PI*QOPorto/QOMadrid index case (II-4) was a male
former smoker of 27 pack-years, diagnosed with severe
COPD at age of 44, and currently receiving home oxy-
gen therapy. He had dyspnea on moderate and small
exertion, and radiological findings of diffuse panlobu-
lar emphysema and isolated bronchiectasis. Liver function
tests were normal. He presented no detectable IEF bands
and his serum AAT levels ranged from 9 to 17 mg/dL
(Figure 1).
The other PI*QOPorto/QOMadrid sibling (case II-3) was
a never smoker asymptomatic female that maintained a
nearly normal respiratory function, but early functional
signs of lung damage ((Transfer coefficient (diffusion
constant) of CO diffusion (KCO) slightly decreased), and
mild signs of lung emphysema, detected by computed
tomography (CT) scan at the age of 41. She also showed
absence of IEF bands, and AAT serum levels between 8
and 15 mg/dL. Her liver function tests were within normal
parameters.
The remaining two siblings (II-1 and II-2) aged 51 and
55, with PI*M/QOPorto genotypes had a moderate AATdeficiency, with AAT serum values around 70 mg/dL,
and IEF revealing a normal electrophoretic pattern, com-
patible with an M phenotype. This partial reduction in the
AAT levels but a normal protein phenotype corresponds
to their heterozygous genotype, constituted by one normal
(M) and one null allele (QOPorto). These subjects suffered
from a moderate congenital mental retardation of unknown
etiology. None of them showed symptoms or signs of
respiratory disease, and their lung function tests remain
normal at present, despite both are former smokers
(smoking exposure of 10 pack-years each one). The CT
scan detected mild basal emphysema in II-1 and no patho-
logical findings in II-2.
Identification of the QOMadrid mutation
The entire sequence of the SERPINA1 gene, including
coding and non-coding regions, was analyzed. DNA se-
quencing of the exon 1C and intron 1C revealed in the
four siblings a heterozygous base substitution G to A
at position +1 of the splice donor site of intron 1C
(NM_000295.4:c.-5 + 1G > A), previously described as
QOPorto splicing mutation [29]. Analysis of the complete
sequence of the SERPINA1 gene showed that this was the
only pathogenic mutation found in individuals II-1 and
II-2 (Figure 2). The heterozygous status for QOPorto allele
in these patients was compatible with their moderate AAT
deficiency.
Interestingly, the other two family members, II-3 and
II-4, who showed a severe AAT deficiency, in addition to
the QOPorto mutation were carriers of a duplication of
the thymine (T) in position +2 of the same splice donor
site of intron 1C (NM_000295.4: c.-5 + 2dupT) (Figure 2).
Since splicing sites are highly conserved sequences, this
variation presumably disrupts the splicing donor site of
this intron. This effect would be compatible with the
strong AAT deficiency that both subjects presented. Since
the whole sequence of the gene, coding and noncoding re-
gions, was analyzed in these two patients, and there was
no other pathogenic change, we assumed reasonably that
this change is a deficient allele, not previously described,
that was termed QOMadrid following the classical no-
menclature agreed by experts in the field, with QO
representing a non-expressing gene at the protein
level, and Madrid the name of the place of origin of the
first carrier of the allele [40,41].
In addition, all four patients were heterozygous for
the M2 (G/A, Arg101His, rs709932) and M3 (A/C,
Glu376Asp, rs1303) common polymorphisms of the
SERPINA1 gene. Sequencing of the expression products
generated by using primers located in exon 1C and exon 5
demonstrated that patients II-1 and II-2, carriers of the
QOPorto allele, only expressed transcripts with the M3 (C,
Asp376) variant. Since QOPorto mutation affects the nor-
mal expression of AAT mRNA, QOPorto mutation in these
Wildtype
QOPorto
QOPorto/QOMadrid
Exon 1C Intron 1c
E1A E1B E1C E2 E3 E4 E5
M2
(Arg101His)
M1
(Val213Ala)
M3
(Glu376Asp)
Figure 2 Results of direct sequencing of the exon 1C-inton 1C boundary region. Schematic representation of SERPINA1 gene is
represented in the top showing position of the non-coding exons 1A, 1B and 1C and coding exons E2 to E5. Location of the common
polymorphisms M1 (exon 3), M2 (exon 2) and M3 (exon 5) of this gene are also displayed. Position of the variants QOPorto and QOMadrid is
marked with an arrow. Sequencing results of the patients are shown below. Comparison between a reference sequence from a normal
individual (top sequence) and sequence from individuals II-1 and II-2 (middle panel) showing a heterozygous G to A change corresponding
to the QOPorto. Bottom panel corresponds to direct sequencing of cases II-3 and II-4 that reveals heterozygosity for both QOPorto and the
new QOMadrid (+2dupT) mutation.
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the M2 (A, His101) but not the M3 (C, Asp376) variant
(Figure 1). Consequently, the QOMadrid mutation found in
patients II-3 and II-4 segregated with the M3 (C, Asp376)
variant.
QOMadrid impairs normal splicing in in silico analysis
Thymine duplication at the site of splicing of intron 1C
(i.e., the QOMadrid mutation) is located in a highly con-
served splicing sequence of vertebrate splice donor sites
and may lead to deregulation of gene expression. Com-
putational predictions of splicing signals demonstrated
disappearance of the constitutive donor splicing signals
in the case of the QOMadrid mutation, similarly to what
happened for the QOPorto splicing mutation. In addition
several putative binding sites for Exonic Splicing En-
hancers (ESE elements), such as SC35, SRp55 or SRp40
splicing factors, were predicted to be also affected by the
duplication of T in position +2 of the QOMadrid allele.
Thus, SC35 site would be disrupted by QOMadrid muta-
tion and the predicted scores for SRp55 or SRp40 were
reduced (Figure 3).Expression analysis of severe AAT deficiency cases
carrying QOPorto and QOMadrid
To further investigate the molecular effect on splicing
and expression of the SERPINA1 gene with the QOMadrid
mutation which co-occurred with QOPorto mutation in
patients II-3 and II-4, expression products generated by
different primer pairs in exons 1A, 1B, 1C and exons 2
and 5 were analyzed (Figure 4A). RT-PCR expression
analysis of fragment E1C-E2 showed normally spliced
products in control liver tissue and peripheral blood, as
well as in the two moderate AAT deficiency patients II-1
and II-2 with PI*M/QOPorto genotype (Figure 4B). In
these patients sequence analysis demonstrated only one
expressed allele based on the Arg101His polymorphism,
corresponding to the normal M3 allele. However, no
expression products were detected in patients carrying
both splicing variants QOPorto and QOMadrid, clearly
indicating that QOMadrid mutation also impairs normal
splicing of intron 1C and represents a new null allele of
the SERPINA1 gene.
We also checked using primers in the E1C-Int1C
whether transcripts including intron 1C sequence were
Figure 3 Schematic representation of the region E1C-Intron 1C containing the mutations QOPorto and QOMadrid. The consensus donor
splicing sequence is disrupted in both the QOPorto mutation and the QOMadrid mutation. Boxes represent the scores of splicing factors obtained
by bioinformatic tools. Several putative binding sites for splicing enhancer elements, SC35, SRp55 or SRp40, were predicted to be affected by
these mutations. In the top panel, duplication of T of the QOMadrid variant cause that site for SC35 disappear, and in the bottom panel the
QOPorto variant cause a reduction of the score value for the SC35 from 3.48 in the reference sequence to 3.12 in the mutated sequence.
WT: wild type sequence.
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to the presence of both intron 1C splicing mutations,
QOPorto and QOMadrid. Similar to what was described for
the QOPorto mutation [29], no expression products
retaining intron 1C sequence were detected indicating
that if these transcripts are synthesized they might be
probably rapidly degraded.
Transcripts that include E1A and E1B were also
analyzed. Amplification of the E1A/E2 fragment in all
patients, normal peripheral blood samples, and in a
normal liver sample analyzed, produced one single
band visible in agarose gel in all cases. Sequencing analysis
revealed that the only mRNA product resulted from the
direct splice of exon 1A to exon 2 (Figure 4C). Alternative
spliced forms, previously described by others in mono-
cytes/macrophages [8,42], were not detected in our sam-
ples. Moreover, in all patients transcripts which include
E1A showed expression of both alleles, since both variants
Arg101 and His101 (G/A) were found. This indicates that
QOPorto and QOMadrid mutations do not impede transcrip-
tion not requiring the splice donor site of intron 1C.
Regarding transcripts which included exon 1B, multiple
expression products were detected after amplification with
primer pair E1B-E2. After cloning, five different products
were identified in patients II-1 and II-2 (Figure 4D). The
most frequent species, as shown by the number of col-
onies, were those including exons 1B joined to 1C and to
exon 2 (named as product [1] in Figure 4D). Alternativeproducts ([2] and [3] in Figure 4D) generated using a
cryptic splice donor site in exon 1B previously described,
producing a 18 bp shorter fragment at the 3′ end of the
exon 1B, were also found [43]. In addition, alternatively
spliced products formed by direct splice of exon 1B to E2
([4] in Figure 4D), as well as transcripts retaining the in-
tron 1B ([5] in Figure 4D), were also found but in less
amount.
In patients with QOPorto and QOMadrid mutations (II-3
and II-4) only two different transcripts species were
detected by using E1B and E2 primer pair. In these cases
both fragments corresponded to RNA products contain-
ing only E1B joined to E2 (Figure 4D), one of the products
previously described using the cryptic splice donor site in
exon 1B [44]. However, these patients do not include E1C
in transcription products since splice donor site of intron
1C is completely disrupted by the presence of QOPorto and
QOMadrid splicing mutations.
Functional assays by hybrid minigenes
The wild type (wt) and the mutant minigenes were func-
tionally assayed in HeLa cells. The wt construct produced
at least 7 different transcript as well as a wide range of
rare splicing isoforms (Figure 5), where the skipping of
both exons 1B and 1C (only with vector exons v1 + v2)
was the most frequent event (51.3%). This isoform resem-
bles the most abundant transcript of AAT in macrophages
without exons 1B and 1C [43]. We also identified four
E1C_E5
E1C_E2
E1A_E2
1A 2
E1B_E2
1C 21B
II-3
II-4
II-1
II-2
21B
A
B
C
D
1C 2 3 4 5
1C 2
[1]
[2]
[3]
[4]
[5]
Figure 4 Expression analysis in the family patients carrying the QOPorto mutation (II-1 and II-2) and the ones carrying both QOPorto and
QOMadrid variants (II-3 and II-4). A) Schematic representation of the SERPINA1 gene. To amplify different transcripts some forward primers in
exons 1A, 1B, and 1C and reverse primers in exons 2 and 5 were designed (arrows). B) RT-PCR amplification of mRNA using primers located in
exon 1C and the reverse primers in exon 2 or exon 5, analyzed in normal hepatocytes (H), the AAT cases, and in a normal peripheral blood
sample (PB). No expression products were found in cases II-3 and II-4 when using exon 1C primer. All the other cases showed a single band of
587 bp corresponding to expression products containing the exon 1C directly spliced to exon 2, or in the case of E1C-E5 the expression product
corresponded to a fragment of 1318 bp with the exon 1C joined to all the coding exons (2 to 5). C) Fragments generated by amplification of
expression products using primers in exon 1A and exon 2. All cases showed expression of a transcript including the exon 1A directly joined to
exon 2. No other alternative splicing variants were found. D) Expression analysis using primers in exon 1B revealed multiple bands meaning that
alternative splicing occurred between exons 1B and 1C. After cloning, we differentiated five different splicing forms, some showed the use of
alternative splicing sites on exon 1B (3 and 4) previously described. One of the transcription species retained the intron 1B (5). Severe DAAT cases
only express transcripts without exon 1C.
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Figure 5 Transcripts detection in wt and splicing mutation minigenes. A) Fluorescent capillary electrophoresis of RT-PCR products generated
by the wild type, c.-5 + 2dupT and c.-5 + 1G > A minigenes. Screenshots of Peak Scanner electropherograms are shown. Fluorescent RT-PCRs
(blue peaks) of wt and mutant minigenes were run in an ABI3130 DNA sequencer with Genescan ROX 500 (red peaks) as size standard. RFU:
Relative Fluorescence Units. B) Quantification of all detected of transcripts (Tr1 to 12) generated by the wild type, or mutants c.-5 + 1G > A (QOPorto)
and c.-5 + 2dupT (QOMadrid) minigenes of the SERPINA1 gene are represented with the mean proportion of each one. Sizes were calculated by the Peak
Scanner software. Depending the use of the alternative splicing sites described for exon 1B and 1C, the deduced transcript composition is: Tr1:
V1-1Cs -V2; Tr2: V1-1Cl -V2; Tr3: V1-1Bs -V2; Tr4: V1-1Bl -V2; Tr5: V1-1Bs -1Cs-V2; Tr6: V1-1Bs -1Cl-V2; Tr7: V1-1Bl -1Cs-V2; Tr8: V1-1Bl -1Cl-V2; Tr9-12:
partial intron retentions. (1Bs and 1Bl: exon1B short and long, respectively; 1Cs and 1Cl: exon 1C short and long, respectively).
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the combination of four splice sites: the canonical donor
and acceptor sites, and one donor (18 nucleotides down-
stream in intron 1B) and one acceptor (3 nucleotides
downstream in exon 1C) cryptic sites (transcripts Tr5,
Tr6, Tr7 and Tr8, together accounting for 22.1%; Figure 5).
Finally, Tr1 and Tr2 would represent transcripts lacking
exon 1B. These results are in accordance to the transcripts
described by Rollini and Fournier (2000) [43]. Therefore,
the splicing pattern of wild type MGserp1a_ex1b-1c mim-
icked that of macrophages cell lines.
Interestingly, mutations c.-5 + 1G > A and c.-5 + 2dupT
triggered the elimination of six transcripts of the wild type
minigene (Tr1, 2, 5, 6, 7, 8) and generated six new ones,
Tr10, Tr11 and Tr12 (c.-5 + 1G > A), and Tr3, Tr4 andTr9 (c.-5 + 2dupT). The V1 + V2 transcript was signifi-
cantly enriched in c.-5 + 1G > A (83.0% vs. 51.3% in wt)
although other three aberrant transcripts (Tr10-12) would
correspond to partial retentions of intron 1C. The new
mutation QOMadrid (c.-5 + 2dupT) induced isoforms Tr3
and 4 that were relatively abundant (12.5 and 34.6%,
respectively) and corresponded to exon 1C skipping
and alternative usage of the two donor sites of intron
1B. This result reproduced the splicing profile of patient
RNA.
Discussion
We have characterized a new splicing variant in the
SERPINA1 gene producing a null allele that we named
PI*QOMadrid following the traditional terms used to
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This new allele increases the short list of null alleles
reported to date, which are characterized by the almost
absence serum AAT [4].
As shown in Table 1, several molecular mechanisms
have been described to be responsible for the lack of
expression of AAT protein including deletion of AAT
coding exons, nonsense mutations producing formation
of premature stop codons or splicing mutations. The
QOMadrid variant corresponded to the fourth splice site
alteration described so far in the SERPINA1 gene. The
three other reported splicing variants were QOWest,
QOBonny blue and QOPorto. The QOWest and QOBonny blue
alleles are caused by alterations in the splice donor and
acceptor sites of intron 2 [4,34], while QOPorto corre-
sponded to a G to A transition in the donor splice site
of intron 1C [29]. Therefore, the QOMadrid adds a new
splicing variant (+2dupT) to the same splicing donor
site of intron 1C.
This new QOMadrid mutation, which occurred in a M3
background, enlarge the number of pathogenic muta-
tions outside the coding sequence of the SERPINA1 gene
and highlight the importance that regulatory regions
might have in the disease. Studies of these regions should
be seriously considered in discordant cases with severe
AAT deficiency where no coding alterations are found.
In the two severe AAT deficiency patients of this family
in Madrid, the new splicing mutation occurred in het-
erozygous state in combination with another splicing
mutation previously described as QOPorto, curiously
both affecting the donor splice site of intron 1C. Both
composite heterozygotes PI*QOPorto/QOMadrid individ-
uals showed extremely low levels of serum AAT and a
practically total absence of detectable plasma protein
by isoelectric focusing, indicating that these changes
strongly affect the AAT synthesis by disrupting the
normal splicing of the intron 1C. In this regard, we
demonstrate that these patients lacked of transcripts
with exon 1C, and therefore of the properly matured
mRNA synthesized by the liver which is the major
source of the AAT mRNA. Nevertheless, these two
composite heterozygotes were able to produce AAT
mRNA transcripts from exons 1A and 1B, which are
probably originated from the macrophage-specific pro-
moter localized in the gene upstream of the liver promoter
[8]. Is it possible then, that the low level of serum AAT
protein detected in severe patients was produced by mac-
rophages or other cells than hepatocytes. However, these
transcripts represent a small proportion of the total AAT
transcription, and may be insufficient to compensate the
negative effects of the splicing mutations in liver cells.
In the index case, the presence of both QOPorto and
QOMadrid mutations likely caused the genetic susceptibil-
ity to early onset emphysema after smoking exposure,similarly to which occur with other null alleles [27]. The
siblings presenting a genotype PI*M/QOPorto showed
AAT serum levels concordant with the presence of a
normal and a mutated allele. Heterozygous status for a
null allele is generally considered to produce enough
normal protein to keep enough antielastase activity in
the lung, and hence the risk of lung disease might be
mild. These patients also presented moderate degree of
mental retardation. Dementia-like syndrome associated
with serpinopaties has been reported [9] but there is no
evidence suggesting that QOPorto could be related with
mental impairment detected in these individuals. Although
splicing variants have been rarely described causing AAT
deficiency, their existence show that correct splicing events
are important for the accurate function of this gene.
Splicing alterations have been described to originate
genetic diseases such as spinal muscular atrophy, neuro-
fibromatosis type I or myotonic dystrophy, among many
others. Numerous disease causing genes undergo alter-
native splicing to regulate expression, and it is estimated
that overall 15% of mutations are located within splicing
sites and more than 20% of missense mutations lie
within predicted splicing elements [45].
Computational analysis of the effect of the new QOMadrid
revealed the disruption of the consensus donor splicing
site sequence. In addition, using exonic splicing enhancers
(ESE) motif predictions it was observed that the variant
mainly eliminate a potential SC35 factor binding site. This
and other ESE sequences have been described to play a
key role in regulating splicing events [46].
Transcriptional analysis of the AAT deficiency family
members allowed us to verify that transcription from
exon 1C, still detected in siblings with PI*M/QOPorto,
was totally impaired in the compound heterozygotes
PI*QOPorto/QOMadrid. The QOMadrid mutation highlights
the importance of exon 1C for the correct expression of
AAT in the liver, in order to ensure the production of
appropriate serum AAT concentrations. Even though
transcripts from the exons 1A and 1B were detected in
the compound heterozygotes, these RNA species might
not be abundant enough to provide acceptable AAT
serum levels.
Moreover, we have constructed and validated the mini-
gene MGserpa1_ex1b-1c in the pSAD vector where the
splicing patterns of mutant and wt minigenes were
clearly distinguished. Consequently, it constitutes a very
valuable tool for the functional and clinical classification
of DNA variants from disease genes, facilitating the dis-
crimination between neutral and deleterious changes.
This approach also allows quantifying the impact on
splicing of a single variant without the interference of
another allele as it occurs in patient RNA. Moreover, at
least 13 different transcripts from the AAT construct were
detected supporting the high sensitivity and resolution of
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as previously reported [39]. Furthermore, the wild type
construct and several cell lines displayed similar splicing
patterns [43] and variant c.-5 + 2dupT in minigene and
patient RNA was associated with exon 1C skipping in
both cases, lending further support to the reproducibility
of minigene assays. Indeed, all the transcripts detected in
macrophage cell lines were identified in our wild type
minigene, including the alternative selection of cryptic
splice sites in intron 1B and exon 1C. 3.
Conclusion
In summary, a new variant in the 5′UTR promoter region
of the SERPINA1 gene causing a new null allele QOMadrid
has been described for a first time. This new variant is
added to the previously described null variants that affect
splicing causing the disease. The minigene system is a
powerful approach to detect variants with an impact on
splicing and have contributed to a better knowledge of this
gene expression step by quantification of normal and ab-
errant alternative transcripts of the SERPINA1 gene.
Similar to what occur with deficient variants located in
exons, which allowed a better understanding of the AAT
structure-function relationships, splicing variants provide
us with more insight into the expression regulation of the
SERPINA1 gene.
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